Phibro Animal Health Corporation (Nasdaq:PAHC) today announced financial results for its first quarter ended September 30, 2021.
-
Highlights for the three months ended September 30, 2021 (compared to the three months ended September 30, 2020)
- Net sales of $215 million, an increase of $20 million, or 10%
- Net income of $7 million, a decrease of $6 million, or 47%
- Diluted EPS of $0.16, a decrease of $0.14, or 47%
- Adjusted EBITDA of $22 million, a decrease of $2 million, or 8%
- Adjusted net income of $10 million, a decrease of $1 million, or 6%
- Adjusted diluted EPS of $0.25, a decrease of $0.02, or 7%
- The Company revised financial guidance for the fiscal year ending June 30, 2022, raising net sales projections by $20 million from a range of $840 - $870 million to $860 - $890 million, and maintaining adjusted EBITDA guidance of $110 - $114 million.
COMMENTARY
“I was most encouraged by first quarter sales performance as it reflects continued growth in the demand for our products, particularly nutritional specialties and vaccines. Overall, our financial performance was in line with internal expectations,” said Jack Bendheim, Phibro’s Chairman, President and Chief Executive Officer.
Jack continued, “While we raised the prices of select products, the increases did not fully compensate for the higher cost of freight, labor, and the unfavorable currency movements that are putting pressure on margins. Subject to normal competitive conditions, we plan to adjust prices further and pass-through incremental freight costs in the form of a surcharge, the benefit of which should be realized in the second half of our fiscal year. Consequently, we are raising full year net sales guidance to $860 - $890 million, while maintaining our previous guidance on adjusted EBITDA.”
QUARTERLY RESULTS
Net sales
Net sales of $214.7 million for the three months ended September 30, 2021, increased $19.5 million, or 10%, as compared to the three months ended September 30, 2020. Animal Health, Mineral Nutrition and Performance Products net sales increased $12.6 million, $3.0 million and $3.8 million, respectively.
Animal Health
Net sales of $141.0 million for the three months ended September 30, 2021, increased $12.6 million, or 10%. Net sales of MFAs and other increased $5.1 million, or 6%, driven by stronger international demand, primarily for poultry and cattle products in the Latin America and Southeast Asia regions, partially offset by timing of certain domestic and other international customer orders. Net sales of nutritional specialty products increased $3.4 million, or 10%, driven by strong international demand in dairy products. Net sales of vaccines increased $4.2 million, or 25%, driven by growth across all major markets, but primarily stronger demand in Eastern Europe and India.
Mineral Nutrition
Net sales of $54.4 million for the three months ended September 30, 2021, increased $3.0 million, or 6%, driven by increased average selling prices, partially offset by lower volumes. The increase in average selling prices is correlated with the movement of the underlying raw material costs.
Performance Products
Net sales of $19.2 million for the three months ended September 30, 2021, increased $3.8 million, or 25%. The increase was driven by strong demand for copper-based products coupled with increased selling prices correlated with underlying raw material costs.
Gross profit
Gross profit of $64.7 million for the three months ended September 30, 2021, increased $0.6 million, or 1%, as compared to the three months ended September 30, 2020. Gross margin decreased 270 basis points to 30.1% of net sales for the three months ended September 30, 2021, as compared to 32.8% for the three months ended September 30, 2020.
Animal Health gross profit decreased $1.3 million due to higher logistics and manufacturing costs, as well as unfavorable geographic and product mix. Mineral Nutrition gross profit increased $1.6 million, driven primarily by higher average selling prices and favorable product mix. Performance Products gross profit increased $0.2 million driven by volumes.
Selling, general and administrative expenses
Selling, general and administrative expenses (“SG&A”) of $50.1 million for the three months ended September 30, 2021, increased $1.6 million, or 3%, as compared to the three months ended September 30, 2020. SG&A for the three months ended September 30, 2020, included $0.6 million of stock-based compensation. Excluding these costs, SG&A increased $2.2 million, or 5%.
Animal Health SG&A increased $1.1 million, due to investments in market expansion initiatives in certain international regions, as well as increased marketing and sales team travel costs. Mineral Nutrition and Performance Products SG&A were comparable to the prior year. Corporate SG&A increased $0.4 million due to incremental investments in strategic initiatives and higher compensation costs, partially offset by the decrease in stock-based compensation.
Interest expense, net
Interest expense, net of $2.9 million for the three months ended September 30, 2021, increased $0.1 million, or 3%, as compared to the three months ended September 30, 2020. Interest expense, net increased primarily due to higher levels of debt outstanding and lower interest income, partially offset by favorable variable borrowing rates.
Foreign currency (gains) losses, net
Foreign currency (gains) losses, net for the three months ended September 30, 2021, amounted to net losses of $2.1 million, as compared to $3.6 million of net gains for the three months ended September 30, 2020. Foreign currency (gains) losses, net primarily arose from intercompany balances, driven by the weakening of the Turkish, Mexican and Brazilian currencies relative to the U.S. dollar.
Provision for income taxes
The provision for income taxes was $3.1 million and $4.2 million for the three months ended September 30, 2021 and 2020, respectively. The effective income tax rate was 31.9% and 25.5% for the three months ended September 30, 2021 and 2020, respectively. The provision for income taxes during the three months ended September 30, 2021, included a $0.4 million expense resulting from changes in uncertain tax positions related to prior years. The effective income tax rate without this expense would have been 27.4% for the three months ended September 30, 2021.
Net income
Net income of $6.5 million for the three months ended September 30, 2021, decreased $5.8 million, as compared to net income of $12.3 million for the three months ended September 30, 2020. Operating income declined $1.1 million, driven by increased SG&A expenses, partially offset by higher gross profit. The increase in gross profit in the Mineral Nutrition and Performance Products segments was partially offset by a decrease in gross profit and gross margin in the Animal Health segment, driven by higher logistics and manufacturing costs, as well as unfavorable geographic and product mix. SG&A expenses increased due to investments in strategic initiatives and increased travel costs. The variance in foreign currency (gains) losses resulted in a $5.8 million unfavorable impact on income before income taxes, while income tax expense decreased $1.1 million.
Adjusted EBITDA
Adjusted EBITDA of $22.5 million for the three months ended September 30, 2021, declined $1.8 million, or 8%, as compared to the three months ended September 30, 2020. Animal Health adjusted EBITDA decreased $2.5 million on lower gross profit and increased SG&A costs. Mineral Nutrition adjusted EBITDA increased $1.5 million, driven by increased gross profit on higher average selling prices and favorable product mix. Performance Products adjusted EBITDA increased $0.2 million driven by increased gross profit. Corporate expenses increased $1.0 million, primarily due to incremental investments in strategic initiatives and higher compensation costs.
Adjusted provision for income taxes
The adjusted effective income tax rates for the three months ended September 30, 2021 and 2020, were 26.4% and 31.0%, respectively. The decrease in our adjusted effective income tax rate was driven primarily by a change in the jurisdictional mix of earnings.
Adjusted net income
Adjusted net income of $10.2 million for the three months ended September 30, 2021, decreased $0.6 million, or 6%, as compared to the three months ended September 30, 2020. The decrease was driven by higher SG&A expenses, partially offset by a lower provision for income taxes. SG&A expenses increased due to incremental investments in strategic initiatives and increased travel costs.
Adjusted diluted EPS
Adjusted diluted EPS was $0.25 for the quarter, a decrease of $0.02, as compared to $0.27 for the three months ended September 30, 2020.
BALANCE SHEET AND CASH FLOWS
- Free cash flow of $21 million for the twelve months ended September 30, 2021
-
3.8x gross leverage ratio as of September 30, 2021
- $406 million total debt
- $106 million adjusted EBITDA for the twelve months ended September 30, 2021
- $97 million of cash and short-term investments on hand and $137 million of available revolving credit (subject to leverage ratio limitations) as of September 30, 2021
REVISED FINANCIAL GUIDANCE
Our revised projections of financial performance for the year ending June 30, 2022, are as follows:
- Net sales of approximately $860.0 – $890.0 million
- Adjusted EBITDA of approximately $110.0 – $114.0 million
- Adjusted net income of approximately $50.7 – $53.3 million
- Adjusted diluted EPS of approximately $1.25 – $1.32
- Adjusted effective tax rate of approximately 29% – 31%
This revised financial guidance includes but is not limited to sales growth across all three business segments, further price adjustments and the pass through of incremental freight costs in the form of a surcharge, where applicable and competitive conditions allow.
We are not providing revised forward-looking guidance for certain GAAP financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measure because we are unable to predict with reasonable certainty the ultimate outcome of certain significant items, including but not limited to the impact of foreign currency exchange gains or losses.
The COVID-19 global pandemic continues to present challenges to the animal health industry, including but not limited to increased material and shipping costs and labor cost increases and shortages.
We will continue to monitor the impact the pandemic is having on our business and adjust our financial guidance, if necessary.
WEBCAST & CONFERENCE CALL DETAILS
Phibro Animal Health Corporation will host a webcast and conference call during which the Company will review its financial results and respond to questions.
Date: |
Wednesday, November 3, 2021 |
|
Time: |
9:00 AM Eastern |
|
Location: |
||
U.S. Toll-Free: |
+1 (888) 330-2022 |
|
International Toll: |
+1 (365) 977-0051 |
|
Conference ID: |
3927884 |
NOTE: To join this conference call, all participants will be required to provide the Conference ID number.
A replay of the webcast will be archived and made available on Phibro’s website.
DISCLOSURE NOTICES
Forward-Looking Statements: This communication contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this communication are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Quarterly Report on Form 10-Q and Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements” and “Risk Factors.” These filings and subsequent filings are available online at www.sec.gov, www.pahc.com, or on request from Phibro.
Non-GAAP Financial Information: We use non-GAAP financial measures, such as adjusted EBITDA and adjusted net income, to assess and analyze our operational results and trends and to make financial and operational decisions. Management uses adjusted EBITDA as its primary operating measure. We report adjusted net income to portray the results of our operations prior to considering certain income statement elements. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this communication should not be considered alternatives to measurements required by GAAP, such as net income, operating income and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliation of non-GAAP financial measures and GAAP financial measures are included in the tables accompanying this communication and/or our Quarterly Report on Form 10-Q and Annual Report on Form 10-K.
Internet Posting of Information: We routinely post information that may be important to investors in the “Investors” section of our website at www.pahc.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Phibro Animal Health Corporation |
||||||||||||||
Consolidated Results of Operations |
||||||||||||||
Three Months |
||||||||||||||
| For the Periods Ended September 30 |
|
2021 |
|
|
2020 |
|
Change |
|||||||
(in millions, except per share amounts and percentages) |
||||||||||||||
| Net sales | $ |
214.7 |
|
$ |
195.2 |
|
$ |
19.5 |
|
10 |
% |
|||
| Cost of goods sold |
|
150.0 |
|
|
131.1 |
|
|
18.9 |
|
14 |
% |
|||
| Gross profit |
|
64.7 |
|
|
64.1 |
|
|
0.6 |
|
1 |
% |
|||
| Selling, general and administrative |
|
50.1 |
|
|
48.4 |
|
|
1.6 |
|
3 |
% |
|||
| Operating income |
|
14.6 |
|
|
15.7 |
|
|
(1.1 |
) |
(7 |
)% |
|||
| Interest expense, net |
|
2.9 |
|
|
2.8 |
|
|
0.1 |
|
3 |
% |
|||
| Foreign currency (gains) losses, net |
|
2.1 |
|
|
(3.6 |
) |
|
5.8 |
|
* | ||||
| Income before income taxes |
|
9.6 |
|
|
16.5 |
|
|
(6.9 |
) |
(42 |
)% |
|||
| Provision for income taxes |
|
3.1 |
|
|
4.2 |
|
|
(1.1 |
) |
(27 |
)% |
|||
| Net income | $ |
6.5 |
|
$ |
12.3 |
|
$ |
(5.8 |
) |
(47 |
)% |
|||
| Net income per share | ||||||||||||||
| basic | $ |
0.16 |
|
$ |
0.30 |
|
$ |
(0.14 |
) |
(47 |
)% |
|||
| diluted | $ |
0.16 |
|
$ |
0.30 |
|
$ |
(0.14 |
) |
(47 |
)% |
|||
| Weighted average common shares outstanding | ||||||||||||||
| basic |
|
40.5 |
|
|
40.5 |
|
||||||||
| diluted |
|
40.5 |
|
|
40.5 |
|
||||||||
| Ratio to net sales | ||||||||||||||
| Gross profit |
|
30.1 |
% |
|
32.8 |
% |
||||||||
| Selling, general and administrative |
|
23.3 |
% |
|
24.8 |
% |
||||||||
| Operating income |
|
6.8 |
% |
|
8.0 |
% |
||||||||
| Income before income taxes |
|
4.5 |
% |
|
8.5 |
% |
||||||||
| Net income |
|
3.0 |
% |
|
6.3 |
% |
||||||||
| Effective tax rate |
|
31.9 |
% |
|
25.5 |
% |
||||||||
Amounts and percentages may reflect rounding adjustments |
||||||||||||||
* Calculation not meaningful |
||||||||||||||
Phibro Animal Health Corporation |
||||||||||||||
Segment Net Sales and Adjusted EBITDA |
||||||||||||||
Three Months |
||||||||||||||
| For the Periods Ended September 30 |
|
2021 |
|
|
2020 |
|
Change |
|||||||
(in millions, except percentages) |
||||||||||||||
| Net Sales | ||||||||||||||
| MFAs and other | $ |
83.8 |
|
$ |
78.7 |
|
$ |
5.1 |
|
6 |
% |
|||
| Nutritional specialties |
|
36.0 |
|
|
32.6 |
|
|
3.4 |
|
10 |
% |
|||
| Vaccines |
|
21.2 |
|
|
17.1 |
|
|
4.2 |
|
25 |
% |
|||
| Animal Health |
|
141.0 |
|
|
128.4 |
|
|
12.6 |
|
10 |
% |
|||
| Mineral Nutrition |
|
54.4 |
|
|
51.4 |
|
|
3.0 |
|
6 |
% |
|||
| Performance Products |
|
19.2 |
|
|
15.4 |
|
|
3.8 |
|
25 |
% |
|||
| Total | $ |
214.7 |
|
$ |
195.2 |
|
$ |
19.5 |
|
10 |
% |
|||
| Adjusted EBITDA | ||||||||||||||
| Animal Health | $ |
27.6 |
|
$ |
30.1 |
|
$ |
(2.5 |
) |
(8 |
)% |
|||
| Mineral Nutrition |
|
4.5 |
|
|
3.0 |
|
|
1.5 |
|
49 |
% |
|||
| Performance Products |
|
2.1 |
|
|
2.0 |
|
|
0.2 |
|
8 |
% |
|||
| Corporate |
|
(11.8 |
) |
|
(10.8 |
) |
|
(1.0 |
) |
(9 |
)% |
|||
| Total | $ |
22.5 |
|
$ |
24.3 |
|
$ |
(1.8 |
) |
(8 |
)% |
|||
| Ratio to segment net sales | ||||||||||||||
| Animal Health |
|
19.6 |
% |
|
23.4 |
% |
||||||||
| Mineral Nutrition |
|
8.3 |
% |
|
5.9 |
% |
||||||||
| Performance Products |
|
11.1 |
% |
|
12.8 |
% |
||||||||
| Corporate (1) |
|
(5.5 |
)% |
|
(5.5 |
)% |
||||||||
| Total (1) |
|
10.5 |
% |
|
12.4 |
% |
||||||||
| (1)reflects ratio to total net sales | ||||||||||||||
| Reconciliation of GAAP Net Income to Adjusted EBITDA | ||||||||||||||
| Net income | $ |
6.5 |
|
$ |
12.3 |
|
$ |
(5.8 |
) |
(47 |
)% |
|||
| Interest expense, net |
|
2.9 |
|
|
2.8 |
|
|
0.1 |
|
3 |
% |
|||
| Provision for income taxes |
|
3.1 |
|
|
4.2 |
|
|
(1.1 |
) |
(27 |
)% |
|||
| Depreciation and amortization |
|
7.9 |
|
|
8.0 |
|
|
(0.2 |
) |
(2 |
)% |
|||
| EBITDA |
|
20.3 |
|
|
27.4 |
|
|
(7.0 |
) |
(26 |
)% |
|||
| Stock-based compensation |
|
- |
|
|
0.6 |
|
|
(0.6 |
) |
* | ||||
| Foreign currency (gains) losses, net |
|
2.1 |
|
|
(3.6 |
) |
|
5.8 |
|
* | ||||
| Adjusted EBITDA | $ |
22.5 |
|
$ |
24.3 |
|
$ |
(1.8 |
) |
(8 |
)% |
|||
| Amounts and percentages may reflect rounding adjustments | ||||||||||||||
| * Calculation not meaningful | ||||||||||||||
Phibro Animal Health Corporation |
||||||||||||||
Adjusted Net Income |
||||||||||||||
Three Months |
||||||||||||||
| For the Periods Ended September 30 |
|
2021 |
|
|
2020 |
|
Change |
|||||||
(in millions, except per share amounts and percentages) |
||||||||||||||
| Adjusted cost of goods sold | $ |
148.5 |
|
$ |
129.5 |
|
$ |
19.0 |
|
15 |
% |
|||
| Adjusted gross profit |
|
66.2 |
|
|
65.7 |
|
|
0.5 |
|
1 |
% |
|||
| Adjusted selling, general and administrative |
|
49.4 |
|
|
47.2 |
|
|
2.2 |
|
5 |
% |
|||
| Adjusted interest expense, net |
|
2.9 |
|
|
2.8 |
|
|
0.1 |
|
3 |
% |
|||
| Adjusted income before income taxes |
|
13.9 |
|
|
15.6 |
|
|
(1.8 |
) |
(11 |
)% |
|||
| Adjusted provision for income taxes |
|
3.7 |
|
|
4.8 |
|
|
(1.2 |
) |
(24 |
)% |
|||
| Adjusted net income | $ |
10.2 |
|
$ |
10.8 |
|
$ |
(0.6 |
) |
(6 |
)% |
|||
| Adjusted net income per share | ||||||||||||||
| diluted | $0.25 |
|
$0.27 |
|
($0.02 |
) |
(7 |
)% |
||||||
| Weighted average common shares outstanding | ||||||||||||||
| diluted |
|
40.5 |
|
|
40.5 |
|
||||||||
| Ratio to net sales | ||||||||||||||
| Adjusted gross profit |
|
30.8 |
% |
|
33.6 |
% |
||||||||
| Adjusted selling, general and administrative |
|
23.0 |
% |
|
24.2 |
% |
||||||||
| Adjusted income before income taxes |
|
6.5 |
% |
|
8.0 |
% |
||||||||
| Adjusted net income |
|
4.8 |
% |
|
5.5 |
% |
||||||||
| Adjusted effective tax rate |
|
26.4 |
% |
|
31.0 |
% |
||||||||
| Reconciliation of GAAP Net Income to Adjusted Net Income | ||||||||||||||
| Net income | $ |
6.5 |
|
$ |
12.3 |
|
$ |
(5.8 |
) |
(47 |
)% |
|||
| Acquisition-related intangible amortization(1) |
|
1.5 |
|
|
1.5 |
|
|
(0.1 |
) |
(3 |
)% |
|||
| Acquisition-related intangible amortization(2) |
|
0.7 |
|
|
0.7 |
|
|
(0.0 |
) |
(3 |
)% |
|||
| Stock-based compensation (2) |
|
- |
|
|
0.6 |
|
|
(0.6 |
) |
* | ||||
| Foreign currency (gains) losses, net(3) |
|
2.1 |
|
|
(3.6 |
) |
|
5.8 |
|
* | ||||
| Adjustments to income taxes(4) |
|
(0.6 |
) |
|
(0.6 |
) |
|
0.0 |
|
* | ||||
| Adjusted net income | $ |
10.2 |
|
$ |
10.8 |
|
$ |
(0.6 |
) |
(6 |
)% |
|||
| Amounts and percentages may reflect rounding adjustments | ||||||||||||||
| * Calculation not meaningful | ||||||||||||||
| (1)Included in cost of goods sold | ||||||||||||||
| (2)Included in selling, general and administrative | ||||||||||||||
| (3)Primarily related to intercompany balances | ||||||||||||||
| (4)Related to the income tax effect of pre-tax income adjustments and the exclusion of certain income tax items | ||||||||||||||
Phibro Animal Health Corporation |
||||||||||||
Operating and Investing Cash Flows |
||||||||||||
Three Months |
||||||||||||
| For the Periods Ended September 30 |
|
2021 |
|
|
2020 |
|
Change |
|||||
(in millions) |
||||||||||||
| EBITDA | $ |
20.3 |
|
$ |
27.4 |
|
$ |
(7.0 |
) |
|||
| Adjustments | ||||||||||||
| Stock-based compensation |
|
- |
|
|
0.6 |
|
|
(0.6 |
) |
|||
| Foreign currency (gains) losses, net |
|
2.1 |
|
|
(3.6 |
) |
|
5.8 |
|
|||
| Interest paid, net |
|
(2.7 |
) |
|
(2.5 |
) |
|
(0.2 |
) |
|||
| Income taxes paid |
|
(3.0 |
) |
|
(5.0 |
) |
|
2.0 |
|
|||
| Changes in operating assets and liabilities and other items |
|
(13.0 |
) |
|
(15.1 |
) |
|
2.1 |
|
|||
| Net cash provided (used) by operating activities | $ |
3.8 |
|
$ |
1.7 |
|
$ |
2.1 |
|
|||
| Short-term investments, net | $ |
(13.0 |
) |
$ |
(6.0 |
) |
$ |
(7.0 |
) |
|||
| Capital expenditures |
|
(7.4 |
) |
|
(7.4 |
) |
|
(0.0 |
) |
|||
| Other investing, net |
|
(0.2 |
) |
|
(0.2 |
) |
|
(0.0 |
) |
|||
| Net cash provided (used) by investing activities | $ |
(20.7 |
) |
$ |
(13.6 |
) |
$ |
(7.0 |
) |
|||
| Net cash flow before financing activities | $ |
(16.8 |
) |
$ |
(11.9 |
) |
$ |
(4.9 |
) |
|||
| Amounts and percentages may reflect rounding adjustments | ||||||||||||
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a diversified global developer, manufacturer and supplier of a broad range of animal health and mineral nutrition products for livestock, helping veterinarians and farmers produce healthy, affordable food while using fewer natural resources. For further information, please visit www.pahc.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102006267/en/
Contacts
Phibro Animal Health Corporation
Damian Finio
Chief Financial Officer
+1-201-329-7300
Or
investor.relations@pahc.com
